Loading...
Loading...
Size: 5mg
Cognitive & Anxiolytic Peptide
In stock · Ships same day · Free shipping over $150
Technical specifications
Molecular Profile
Synthetic heptapeptide derived from the immunopeptide tuftsin.
Storage Requirements
Lyophilized (powder)
-20°C · stable long-term
Reconstituted / in solution
2-8°C · use within 30 days
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analog of tuftsin (Thr-Lys-Pro-Arg), the endogenous immunomodulatory tetrapeptide derived from the Fc domain of immunoglobulin G. The Pro-Gly-Pro C-terminal extension confers resistance to aminopeptidase degradation, significantly extending Selank's biological half-life compared to native tuftsin. At the molecular level, published peer-reviewed research demonstrates that Selank modulates GABAergic neurotransmission by allosterically enhancing GABA-A receptor sensitivity, increases serotonin metabolism in the frontal cortex and hippocampus, and stabilizes brain-derived neurotrophic factor (BDNF) mRNA expression — collectively producing anxiolytic-like effects in preclinical behavioral models including elevated plus maze, open field, and conflict paradigms without sedation, motor impairment, or dependence potential. Additionally, Selank retains the immunomodulatory properties of its parent compound tuftsin, enhancing monocyte phagocytic activity, IL-6 production, and natural killer cell function. What distinguishes Selank from other anxiolytic compounds is its dual neurotropic-immunomodulatory profile — it simultaneously modulates anxiety-related neurotransmitter systems and innate immune function through a single peptide, a combination not achieved by conventional anxiolytic drugs. Selank has been approved as a registered medication in Russia for anxiety and neurasthenia, and current scientific investigation continues in stress-related cognitive impairment, immune-brain axis signaling, and gene expression profiling of Selank-responsive neuronal pathways.
Published preclinical behavioral studies demonstrate that Selank produces anxiolytic-like effects in elevated plus maze, open field, and Vogel conflict paradigms comparable in magnitude to benzodiazepines, but critically without sedation, motor impairment, amnesia, or physical dependence potential. The anxiolytic mechanism involves allosteric modulation of GABA-A receptor sensitivity combined with stabilization of serotonin metabolism in the frontal cortex, providing a dual-pathway approach to anxiety-related neurotransmitter imbalance.
Selank enhances GABAergic inhibitory neurotransmission by increasing GABA-A receptor sensitivity to endogenous GABA without directly binding the benzodiazepine site, thereby improving the balance between excitatory and inhibitory neural signaling. Published research demonstrates that this allosteric modulation produces calming effects while preserving cognitive clarity and psychomotor performance — a pharmacological profile that distinguishes Selank from conventional GABAergic anxiolytics that impair learning and memory.
Selank improves memory storage and retrieval through its combined effects on monoamine neurotransmitter systems and neurotrophic factor expression. Published research reports stabilization of BDNF mRNA in hippocampal neurons and enhanced serotonin turnover in memory-associated brain regions, supporting improved long-term potentiation and memory trace consolidation. The anxiolytic component may additionally improve cognitive performance by reducing stress-related interference with attentional and mnemonic processes.
Published research protocols reference intranasal administration 2-3 times daily. Store refrigerated at 2-8°C.
Every batch is independently analyzed by a third-party laboratory for purity and identity before release. A batch-specific Certificate of Analysis (COA) is available for each lot.
Purity
99.3%
Lab
Janoshik Analytical Laboratory
Batch
SELANK-2025-001
Test Date
2025-03-20
Orders placed before our daily cutoff ship the same business day. Free shipping on orders over $150, with tracking emailed as soon as your order leaves our facility.
Shipment protection covers your order against loss or damage in transit — if a protected order is lost or arrives damaged, our support team will arrange a replacement or resolution.
For in-vitro research and laboratory use only. This product is not a drug, supplement, food, or cosmetic, and has not been evaluated by the FDA.
Use is restricted to qualified researchers and laboratories operating within all applicable institutional, legal, and ethical guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Selank in lyophilized form should be stored at -20°C for long-term stability, where it remains viable for up to 24 months. The Pro-Gly-Pro C-terminal extension provides enhanced protease resistance compared to native tuftsin, contributing to good stability in both lyophilized and reconstituted forms. Once reconstituted, store at 2-8°C and use within 30 days. For intranasal research protocols, preparing single-use aliquots is recommended.
Every Selank batch is independently tested by Janoshik Analytical Laboratory using HPLC for purity (99%+), mass spectrometry to confirm the heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (MW 751.9 Da), and amino acid composition analysis. The proline-rich sequence is verified to ensure correct folding and receptor binding affinity. Sterility and endotoxin testing are performed on every batch, with COAs available for all products.
Yes, Certificates of Analysis documenting HPLC purity, mass spectrometry identity confirmation, and sterility testing are available for every Selank batch. You can find them on the product page under the Lab Results section, or contact support@pepcelllabs.com for specific batch documentation.
Once reconstituted for intranasal administration, Selank should be stored at 2-8°C and used within 28-30 days. Selank is relatively stable among heptapeptides due to its proline-rich sequence, which resists common aminopeptidase and carboxypeptidase degradation pathways. However, avoid repeated temperature cycling that can accelerate deamidation of the threonine residue.
Selank is sold strictly for in-vitro research, laboratory use, and educational purposes. While Selank is approved as a registered anxiolytic medication in Russia and has been used clinically for anxiety disorders and neurasthenia since 2009, it has not undergone FDA-regulated clinical trials and is not approved in Western regulatory jurisdictions. This product is not intended for human consumption or self-administration. Always consult applicable regulations in your jurisdiction.
